Krilogy Financial LLC Purchases 13,129 Shares of Exact Sciences Corporation $EXAS

Krilogy Financial LLC increased its position in Exact Sciences Corporation (NASDAQ:EXAS) by 30.7% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 55,845 shares of the medical research company’s stock after buying an additional 13,129 shares during the quarter. Krilogy Financial LLC’s holdings in Exact Sciences were worth $3,055,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also added to or reduced their stakes in the company. Westside Investment Management Inc. increased its position in Exact Sciences by 100.0% in the 3rd quarter. Westside Investment Management Inc. now owns 542 shares of the medical research company’s stock valued at $31,000 after acquiring an additional 271 shares during the period. True Wealth Design LLC grew its stake in shares of Exact Sciences by 951.8% in the second quarter. True Wealth Design LLC now owns 589 shares of the medical research company’s stock worth $31,000 after purchasing an additional 533 shares during the last quarter. Country Trust Bank acquired a new stake in Exact Sciences in the second quarter valued at $32,000. Bessemer Group Inc. increased its holdings in Exact Sciences by 1,980.6% in the second quarter. Bessemer Group Inc. now owns 645 shares of the medical research company’s stock valued at $34,000 after purchasing an additional 614 shares during the period. Finally, Quent Capital LLC bought a new position in Exact Sciences during the 3rd quarter worth $48,000. 88.82% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several brokerages have recently weighed in on EXAS. Leerink Partners cut Exact Sciences from a “strong-buy” rating to a “hold” rating in a research note on Thursday, November 20th. Piper Sandler cut Exact Sciences from an “overweight” rating to a “hold” rating and set a $105.00 target price on the stock. in a report on Monday, November 24th. BTIG Research downgraded shares of Exact Sciences from a “buy” rating to a “neutral” rating in a research report on Thursday, November 20th. TD Cowen downgraded shares of Exact Sciences from a “buy” rating to a “hold” rating in a research report on Tuesday, November 25th. Finally, Craig Hallum cut shares of Exact Sciences from a “buy” rating to a “hold” rating and set a $105.00 price objective for the company. in a research report on Friday, November 21st. Two investment analysts have rated the stock with a Buy rating, twenty-one have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $89.56.

Exact Sciences Stock Up 0.1%

Exact Sciences stock opened at $103.43 on Thursday. The company has a market capitalization of $19.74 billion, a PE ratio of -19.44, a PEG ratio of 2.44 and a beta of 1.42. Exact Sciences Corporation has a 12-month low of $38.81 and a 12-month high of $103.54. The firm’s fifty day moving average is $102.02 and its 200 day moving average is $74.98. The company has a quick ratio of 2.44, a current ratio of 2.72 and a debt-to-equity ratio of 0.93.

Insider Activity

In other news, EVP Jacob A. Orville sold 5,000 shares of the firm’s stock in a transaction dated Wednesday, November 19th. The stock was sold at an average price of $75.00, for a total value of $375,000.00. Following the completion of the sale, the executive vice president directly owned 23,237 shares in the company, valued at $1,742,775. This trade represents a 17.71% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. 1.20% of the stock is owned by company insiders.

Exact Sciences Profile

Exact Sciences Corporation is a molecular diagnostics company headquartered in Madison, Wisconsin, dedicated to the early detection and prevention of cancer. The company’s flagship product, Cologuard®, is a noninvasive, stool-based DNA screening test for colorectal cancer that was developed in collaboration with the Mayo Clinic. By combining DNA mutation analysis with hemoglobin detection, Cologuard aims to improve screening adherence and identify cancers and precancerous lesions in average-risk adults.

Since its founding in 1995, Exact Sciences has expanded its portfolio through strategic acquisitions and internal research and development.